Buy Like Buffett
Watchlist

Flagship explainer

What drives Coherus Oncology, Inc.’s return on equity?

ROE is five filed business factors multiplied together.

DuPont return on equity factor treeReturn on equity branches into tax burden, interest burden, operating margin, asset turnover, and the equity multiplier.Return on equity−473%Tax burden−92%net income ÷ pretax incomeInterest burden101%pretax ÷ operating incomeOperating margin−430%operating income ÷ revenueAsset turnover0.12×revenue ÷ average assetsEquity multiplier-9.96×average assets ÷ average equityAs of 2025-12-31 · 1 SEC filing sourceBuy Like Buffett · buylikebuffett.com
DuPont source inputs
InputValueFiscal yearSource
$168MFY2025
  • 10-K · FY 2025Filing detailsAccession 0001104659-26-025308 · filed Mar 9, 2026
Income before tax−$183MFY2025
  • 10-K · FY 2025Filing detailsAccession 0001104659-26-025308 · filed Mar 9, 2026
Operating income−$181MFY2025
  • 10-K · FY 2025Filing detailsAccession 0001104659-26-025308 · filed Mar 9, 2026
$42.2MFY2025
  • 10-K · FY 2025Filing detailsAccession 0001104659-26-025308 · filed Mar 9, 2026
Ending assets$258MFY2025
  • 10-K · FY 2025Filing detailsAccession 0001104659-26-025308 · filed Mar 9, 2026
Beginning assets$449MFY2024
  • 10-K · FY 2024Filing detailsAccession 0001104659-26-025308 · filed Mar 9, 2026
$61MFY2025
  • 10-K · FY 2025Filing detailsAccession 0001104659-26-025308 · filed Mar 9, 2026
−$132MFY2024
  • 10-K · FY 2024Filing detailsAccession 0001104659-26-025308 · filed Mar 9, 2026
Source: · event Dec 31, 2025 · retrieved Oct 18, 2026 · annual-row source set
Embed this chart

View the full Coherus Oncology, Inc. analysis at Buy Like Buffett